OncoBact™: Oncolytic Bacteria Platform with Precision Targeting

Online Inquiry

Name *

Email *

Phone *

Services Interested *

Project Description

Please note that we are not a pharmacy or clinic, so we are unable to see patients and do not offer diagnostic and treatment services for individuals.

Bacterial Strain Screening

In the development of oncolytic bacteria therapy, selecting the appropriate bacterial strain is crucial. Our bacterial strain screening service combines advanced technology and a professional team to ensure you obtain the most suitable strain, laying a solid foundation for your therapy development. With our extensive strain library and cutting-edge screening technologies, we can efficiently identify strains that not only target tumor cells effectively but also maintain high safety standards. At Alfa Cytology, our team of experts, with years of experience in microbial genetics and oncology, is dedicated to providing you with strains that are optimized for therapeutic efficacy and ready for further genetic engineering to meet your specific research and development goals.

Introduction to Bacterial Strain Screening

Oncolytic bacteria therapy is an innovative approach that uses bacteria to selectively colonize tumor tissues and directly or indirectly kill cancer cells. However, selecting the right bacterial strain is essential for ensuring the safety and efficacy of the therapy. Oncolytic bacterial strain screening involves identifying and selecting bacterial strains with the ability to selectively infect and destroy cancer cells, potentially leading to new cancer therapies. This process includes both identifying naturally occurring oncolytic bacteria and engineering existing strains for enhanced tumor-targeting and therapeutic efficacy. Through the scientific screening process, it can lay the foundation for subsequent genetic engineering and clinical applications. Bacteria Strain screening focuses on the following key aspects:

Ensuring bacteria can specifically grow in the tumor microenvironment.
Reducing the pathogenicity of bacteria to enhance treatment safety.
Selecting strains with optimal oncolytic activity to enhance therapeutic effects.

Fig. 1 Schematic illustration of isolation of extremely effective anticancer bacteria from solid tumors. (Goto, Y., et al., 2023)

Common Bacterial Strains for Oncolytic Bacteria Therapy

A table listing bacteria commonly used in oncolytic bacteria therapy development:

Bacterial Strains	Features and Advantages	Applications
Salmonella	Naturally targets the tumor microenvironment, low pathogenicity, and easy genetic engineering.	Suitable for oncolytic therapy of various solid tumors.
Clostridium	Grows in hypoxic environments, ideal for targeting the interior of tumors.	Used for treating tumors with significant hypoxic environments, such as certain solid tumors.
Escherichia coli (E. coli)	Easy to culture and genetically modify, capable of delivering multiple therapeutic molecules.	Suitable for oncolytic therapies requiring efficient gene expression and molecular delivery.
Listeria monocytogenes	Has immunostimulatory properties, enhancing antitumor immune responses.	Used in combination therapies involving immunotherapy and oncolytic bacteria therapy.

Our Services

At Alfa Cytology, we offer comprehensive bacterial strain screening services, combining advanced technology and a professional team to help you find the most suitable oncolytic bacterial strain and accelerate your therapy development.

Comprehensive Strain Library

Alfa Cytology maintains an extensive library of bacterial strains, including Salmonella, Clostridium, E. coli, and Listeria. These strains are rigorously selected to ensure diversity and scientific validity.

Rigorous Safety Assessment

Alfa Cytology conducts pathogenicity and toxicity analyses to ensure the selected strains are safe and suitable for oncolytic therapy.

Customized Screening Solutions

Alfa Cytology provides customized screening services tailored to your specific needs (e.g., tumor type or therapeutic goals), meeting individual requirements.

Collaboration and Support

Alfa Cytology offers full support from screening to subsequent development, including technical support and consulting services, ensuring you have the best experience.

How We Select the Right Strain

Targeting and Specificity
Selecting bacterial strains that can specifically target the tumor microenvironment, ensuring efficient colonization in tumor tissues.
Safety
Evaluating the pathogenicity and toxicity of strains to ensure safety during therapy.
Oncolytic Activity
Assessing the oncolytic capability of strains to ensure their effectiveness in killing tumor cells.
Immunomodulatory Capacity
Selecting bacteria that can activate the immune system to enhance therapeutic effects.
Genetic Engineering Potential
Choosing strains that are easy to genetically modify to enhance their therapeutic capabilities.

In the field of cancer therapy, Alfa Cytology offers one-stop oncolytic bacterial therapy development platform, providing a comprehensive solution for your oncolytic bacterial therapy development. Contact us today to learn more about our bacterial strain screening services and how we can help accelerate your oncolytic bacterial therapy development.

Reference

Goto, Y., et al. Discovery of Intratumoral Oncolytic Bacteria Toward Targeted Anticancer Theranostics. Advanced science (Weinheim, Baden-Wurttemberg, Germany). 2023, 10(20): e2301679.

For research use only.